Acidipropionibacterium jensenii: A Rising Star in Live Biotherapeutic Products (LBPs)
The landscape of modern medicine is shifting from broad-spectrum chemical interventions toward the precision of biological systems. At the heart of this revolution lies the human microbiome and the commensal bacteria that have co-evolved with us for millennia. Among these, Acidipropionibacterium jensenii (formerly known as Propionibacterium jensenii) has emerged as a powerhouse candidate for Live Biotherapeutic Products (LBPs). As a Contract Research Organization (CRO) dedicated to the frontiers of preclinical research, we recognize that the path from identifying a promising strain to achieving regulatory approval is fraught with complexity. This profile serves as a comprehensive gateway into the world of A. jensenii, exploring its biological significance, its burgeoning role in disease treatment, and the specialized preclinical infrastructure we offer to accelerate your therapeutic pipeline.
Overview: The Biology and Character of Acidipropionibacterium jensenii
Acidipropionibacterium jensenii belongs to the family Propionibacteriaceae, a group of Gram-positive, non-spore-forming, anaerobic to aerotolerant bacteria. Characterized by their pleomorphic rod shape, these organisms are perhaps best known in the food industry for their role in Swiss-type cheeses, where they produce the characteristic "eyes" and flavor through the fermentation of lactate into propionate, acetate, and carbon dioxide.
However, in the context of human health, A. jensenii is much more than a fermentation workhorse. It is a frequent inhabitant of the human skin and various mucosal surfaces, including the vaginal tract. Its primary metabolic hallmark, the production of propionic acid, is of significant interest to researchers. Propionic acid is a short-chain fatty acid (SCFA) that plays a critical role in modulating host immune responses, maintaining epithelial barrier integrity, and inhibiting the growth of pathogenic organisms. Furthermore, A. jensenii is recognized for its "Generally Recognized as Safe" (GRAS) status and its resilience in the gastrointestinal environment. It can survive the harsh acidity of the stomach and the detergent-like effects of bile salts, allowing it to reach the colon or other target sites in a viable state. This robustness, combined with its ability to synthesize essential vitamins like B12 (cobalamin) and secrete potent antimicrobial proteins known as propionicins, positions it as an ideal chassis for biotherapeutic development.
Our Preclinical Research Services for A. jensenii
Navigating the transition from a laboratory isolate to a clinical-grade LBP requires rigorous validation. Our CRO provides a specialized suite of services tailored specifically to the unique requirements of propionic acid bacteria.
Strain Characterization and Genomic Profiling
We begin by establishing a high-resolution "fingerprint" of your strain. Using Whole Genome Sequencing (WGS), we identify key metabolic pathways, antibiotic resistance genes (to ensure safety and lack of horizontal gene transfer), and virulence factor screenings. This foundational data is essential for regulatory filings and intellectual property protection.
In Vitro Functional Assays
Before moving into animal models, we utilize high-throughput screening to quantify the therapeutic outputs of A. jensenii. This includes:
SCFA Quantification: Measuring propionic and acetic acid production under simulated physiological conditions.
Adhesion Testing: Evaluating the strain's ability to adhere to human intestinal cell lines (like Caco-2) to predict colonization potential.
Pathogen Inhibition: Co-culture assays to determine the strain's efficacy against pathogens such as E. coli or C. difficile.
Advanced In Vivo Models
We offer a range of animal models designed to mimic human disease states. Our facilities include germ-free and gnotobiotic environments, allowing for the study of A. jensenii in a controlled microbial vacuum. We specialize in:
DSS-Induced Colitis Models: To test anti-inflammatory efficacy.
Xenograft Models: For oncological applications.
Vaginal Colonization Models: Utilizing specialized rodent models to track the persistence and protective effects of the strain.
Pharmacokinetics and Biodistribution
Understanding where the bacteria go and how long they stay is a regulatory requirement. We utilize bioluminescence imaging and qPCR-based tracking to monitor the transit of A. jensenii through the host system, ensuring it reaches the target site and is cleared appropriately.
Products to Support Your Research
To complement our service offerings, we provide high-quality biological materials and tools specifically optimized for Acidipropionibacterium research.
Purified Metabolites and Propionicins
For researchers looking to study the "postbiotic" effects of the strain, we offer purified fractions of A. jensenii culture supernatants. This includes concentrated propionic acid and isolated antimicrobial peptides (Propionicin T1, etc.) for use in comparative studies.
Reference Strains and Engineered Variants
We maintain a library of characterized A. jensenii strains for use as positive controls. Additionally, we offer custom genetic modification services, such as GFP-tagging, to allow for easier visualization in complex biological matrices.
This product contains high-quality, intact genomic DNA isolated from Acidipropionibacterium jensenii Genomic DNA. It is a purified and ready-to-use DNA sample, ideal for a wide range of molecular biology applications, including PCR, qPCR, and Next-Generation Sequencing.
Acidipropionibacterium jensenii DNA Standard product can be used for quantitative research and analysis, assay development, verification, and validation, and laboratory quality control.
Research Application: Targeting Disease with A. jensenii
The therapeutic potential of Acidipropionibacterium jensenii is currently being mapped across several clinical domains. Its multi-modal mechanism of action, ranging from metabolic byproduct secretion to direct immune signaling, allows it to address various pathologies.
1. Gastrointestinal Health and Inflammatory Bowel Disease (IBD)
The most prominent area of research involves IBD, including Crohn’s disease and ulcerative colitis. A. jensenii exerts a protective effect by increasing the concentration of SCFAs in the gut. These metabolites serve as the primary energy source for colonocytes and stimulate the production of regulatory T cells (Tregs). By promoting an anti-inflammatory environment, A. jensenii helps to dampen the overactive immune response characteristic of IBD. Studies have shown that its presence can reduce the secretion of pro-inflammatory cytokines such as TNF-α and IL-6.
2. Colorectal Cancer (CRC) Prevention
A fascinating area of study is the pro-apoptotic effect of A. jensenii on colon cancer cells. Research indicates that the SCFAs produced by this strain can induce programmed cell death in malignant cells without harming healthy tissue. This occurs through the inhibition of histone deacetylases (HDACs), which leads to the re-expression of tumor-suppressor genes.
3. Vaginal Health and Microbiome Restoration
In the female reproductive tract, A. jensenii acts as a guardian. It produces lactic acid and other antimicrobial substances that lower the pH of the vaginal environment, making it inhospitable to pathogens like Gardnerella vaginalis. Research is exploring its use as a probiotic intervention to prevent bacterial vaginosis (BV) and yeast infections, offering a biological alternative to traditional antibiotics.
4. Immune Modulation and Allergy
Recent preclinical models suggest that the surface proteins of A. jensenii can interact with Toll-like receptors (TLRs) on dendritic cells. This interaction can shift the immune system away from an allergic Th2 response toward a more balanced Th1 response, suggesting potential applications in treating atopic dermatitis and other allergic conditions.
Our Advantages: Why Partner With Us?
Choosing a CRO for Live Biotherapeutic research is a decision that impacts the speed and success of your drug development. We offer several distinct advantages:
Anaerobic Expertise
Unlike generalist CROs, we have a dedicated anaerobic infrastructure. Propionibacteria are sensitive to oxygen during certain growth phases; our specialized chambers and handling protocols ensure the highest viability.
Regulatory Alignment
Our preclinical protocols are designed with FDA and EMA guidelines for LBPs in mind. We help you generate the "Chemistry, Manufacturing, and Controls" (CMC) data early in the process.
Multidisciplinary Team
Our staff includes microbiologists, immunologists, and pharmacologists who work together to provide a holistic view of how A. jensenii interacts with the host.
Tailored Solutions
We don't believe in one-size-fits-all. Every project is customized to the specific therapeutic goal, whether it's a topical cream for skin health or an enteric-coated capsule for IBD.
Acidipropionibacterium jensenii stands at the threshold of a new era in microbiome-based medicine. Its robust nature, combined with its profound metabolic influence on the host, makes it a prime candidate for treating inflammatory, oncological, and infectious diseases. However, the journey from a promising isolate to a life-changing therapy requires precision, specialized knowledge, and a commitment to scientific excellence. As a leader in the preclinical research of Live Biotherapeutics, our company is uniquely positioned to be your partner in this journey. We provide the tools, the technology, and the expertise to transform your vision into a clinical reality. Whether you are in the early stages of strain selection or preparing for an IND filing, we invite you to leverage our specialized capabilities.
Is Acidipropionibacterium jensenii safe for human consumption?
Yes, it has a long history of safe use in the food industry and is generally regarded as safe (GRAS). However, for therapeutic use, it must undergo specific safety assessments, including antibiotic susceptibility testing and toxicology studies in animals, all of which we provide.
How does A. jensenii differ from common probiotics like Lactobacillus?
While both produce beneficial acids, A. jensenii is unique in its high production of propionic acid and its ability to synthesize Vitamin B12. It also occupies a different ecological niche and possesses distinct surface proteins that interact differently with the immune system.
Can you help with the formulation of the final product?
Yes. We offer stability testing and formulation development to ensure that the bacteria remain viable throughout their shelf life and survive the journey to their intended site of action in the body.
What is the typical timeline for a preclinical study?
While it varies based on the complexity of the model, a standard pilot study usually takes 3 to 6 months, while comprehensive regulatory-track studies can take 12 months or more.
Online Inquiry
For Research Use Only. Not intended for use in
food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
